CAMPTH-1H&TACROLIMUS FOLLOWED BY IMMUNOSUPPRESS WITHDRAWAL IN LIVER TRANSPLANTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if 2 doses of Campath-1H, followed by one anti-rejection drug called tacrolimus (Prograf), will be safe and effective in preventing rejection of the donor liver. This study will also evaluate the ability of the Campath-1H to induce "tolerance". Tolerance is when the body no longer tries to reject the transplanted liver even when you are not taking immunosuppression. During this study, the anti-rejection medication (tacrolimus) used to prevent rejection will be gradually withdrawn, beginning one year after liver transplant liver function is stable. If it is determined that the subject can gradually withdraw tacrolimus and then the subject will be re-consented to take part in the withdrawal portion of this study. The withdrawal component will last one year and involve weekly and bi-weekly visits to allow a gradual weaning of the tacrolimus.